4 reports of this reaction
1.5% of all AMMONIA N 13 reports
#11 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #11 most commonly reported adverse reaction for AMMONIA N 13, manufactured by 3D Imaging Drug Design and Development LLC. There are 4 FDA adverse event reports linking AMMONIA N 13 to DRUG HYPERSENSITIVITY. This represents approximately 1.5% of all 259 adverse event reports for this drug.
Patients taking AMMONIA N 13 who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is a less commonly reported adverse event for AMMONIA N 13, but still significant enough to appear in the safety profile.
In addition to drug hypersensitivity, the following adverse reactions have been reported for AMMONIA N 13:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 4 FDA reports for AMMONIA N 13. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 1.5% of all adverse event reports for AMMONIA N 13, making it a notable side effect.
If you experience drug hypersensitivity while taking AMMONIA N 13, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.